Human ghrelin is a 28-amino acid peptide first identified to induce growth hormone secretion via its binding to the growth hormone secretagogue receptor (GHSR-1a) and mainly produced by cells in the fundus of the stomach. Ghrelin can inhibit inflammatory responses, attenuate organ injury, maintain cardiovascular stability, and reduce mortality in young septic animals. Administration of human ghrelin to human considers to be safe.
Human growth hormone is a strong anabolic hormone that enhances protein synthesis, promoting tissue recovery and improving host defenses. Human growth hormone has already been FDA-approved to treat children with various forms of short stature as well as adults with short bowel syndrome, growth hormone deficiency, or AIDS-associated cachexia.
TheraSource has discovered that growth hormone can also function as a ghrelin sensitizing agent. Combination therapy of ghrelin and growth hormone can be a novel therapeutic strategy for certain medical conditions.